NATICK, Mass., Dec. 2, 2013 (GLOBE NEWSWIRE) -- Karyopharm Therapeutics Inc. (Nasdaq:KPTI), a clinical-stage pharmaceutical company focused on the discovery and development of novel first-in-class drugs directed against nuclear transport targets for the treatment of cancer and other major diseases, announced today that Karyopharm will host an investor reception and webcast at the 55th American Society of Hematology (ASH) Annual Meeting and Exposition, which is taking place December 7-10, 2013 in New Orleans.
The investor reception will take place on Monday, December 9th, 2013, from 12:00 p.m. — 1:30 p.m. CST (1:00 p.m. — 2:30 p.m. EST), and will include a discussion of upcoming milestones as well as interim results being presented at ASH from the Phase 1 trial of Selinexor, Karyopharm's lead drug candidate, in hematologic malignancies.
The reception will be webcast beginning at 12:00 p.m. CST (1:00 p.m. EST), which along with an accompanying slide presentation and replay of the event, will be available on Karyopharm's website, www.karyopharm.com, under the "Investors" tab.
About Karyopharm
Karyopharm Therapeutics Inc. (Nasdaq:KPTI) is a clinical-stage pharmaceutical company focused on the discovery and development of novel first-in-class drugs directed against nuclear transport targets for the treatment of cancer and other major diseases. Karyopharm's Selective Inhibitors of Nuclear Export (SINE) compounds function by preventing the export of tumor suppressor proteins from the nucleus of a cell, thereby leading to their accumulation in the nucleus, which subsequently reinitiates and amplifies their tumor suppressor function. Karyopharm was founded by Dr. Sharon Shacham and is located in Natick, Massachusetts.
CONTACT: Beth DelGiacco
Stern Investor Relations, Inc.
beth@sternir.com
212-362-1200